Table 4 –

Checklist of reporting model input in diabetes health economics studies.

Model input	Checkbox	Comments (e.g., justification if not reported)
Simulation cohort
Baseline age
Ethnicity/race
BMI/weight
Duration of diabetes
Baseline HbA1C, lipids, and blood pressure
Smoking status
Comorbidities
Physical activity
Baseline treatment
Treatment intervention
Type of treatment
Treatment algorithm for HbA1c evolution over time
Treatment algorithm for other conditions (e.g., hypertension, dyslipidemia, and excess weight)
Treatment initial effects on baseline biomarkers
Rules for treatment intensification (e.g., the cutoff HbA1C level to switch the treatment, the type of new treatment, and whether the rescue treatment is an addition or substitution to the standard treatment)
Long-term effects, adverse effects, treatment adherence and persistence, and residual effects after the discontinuation of the treatment
Trajectory of biomarkers, BMI, smoking, and any other factors that are affected by treatment Cost
Differentiated by acute event in first year and subsequent years
Cost of intervention and other costs (e.g., managing complications, adverse events, and diagnostics)
Please report unit prices and resource use separately and give information on discount rates applied
Health state utilities
Operational mechanics of the assignment of utility values (i.e., utility- or disutility-oriented)
Management of multihealth conditions
General model characteristics
Choice of mortality table and any specific event-related mortality
Choice and source of risk equations
If microsimulation: number of Monte-Carlo simulations conducted and justification
Components of model uncertainty being simulated (e.g., risk equations, risk factor trajectories, costs, and treatment effect); number of simulations and justification
BMI, body mass index; HbA1c, glycated hemoglobin.